2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?

Why It Matters

The cycle underscores how capital can outpace scientific readiness, reshaping investor expectations and steering biotech toward later‑stage, data‑driven financing.

Key Takeaways

• 2021 saw 99 biotech IPOs, $15.6B raised.
• Many 2021 IPOs now face bankruptcy or pivots.
• Verve Therapeutics sold to Eli Lilly for $1.3B.
• Caribou Biosciences cut staff, refocused after setbacks.
• 2025 shows renewed megarounds for late‑stage biotech.

Pulse Analysis

The 2021 biotech IPO boom was a textbook case of pandemic‑induced liquidity meeting scientific ambition. Venture capital, public markets, and government stimulus converged, flooding the sector with record funding. Companies leveraged the hype to list early, often on the promise of nascent platforms rather than robust clinical data, inflating valuations and creating a crowded public‑market landscape. This influx not only set a new benchmark for capital raised but also seeded a wave of over‑optimistic expectations that would later prove unsustainable.

When the initial excitement faded, the market forced a hard reset. Firms that lacked mature pipelines or operational depth saw their share prices collapse, and several filed for bankruptcy. The experience highlighted a critical lesson: financial momentum cannot substitute for biological validation. Companies like Verve Therapeutics, which stayed true to its gene‑editing focus, secured a $1.3 billion acquisition by Eli Lilly, demonstrating that disciplined science can translate into outsized returns. Conversely, Caribou Biosciences and Invivyd faced workforce cuts and strategic pivots after setbacks, illustrating the volatility that accompanies premature public listings.

By mid‑2025 the sector is recalibrating toward later‑stage financing and selective IPOs. Investors now prioritize companies with clear clinical milestones, as evidenced by the surge in megarounds for Phase III‑ready programs such as Kailera’s obesity asset and Tubulis’s antibody‑drug conjugate. The modest tally of 11 biotech IPOs this year reflects a more measured approach, favoring data‑driven valuations over hype. This disciplined capital environment is likely to foster sustainable growth, encouraging biotech firms to build solid infrastructure before seeking public markets, and positioning the industry for steady innovation in the post‑pandemic era.